Table 2 Changes in peak incremental exercise data after pulmonary rehabilitation with ghrelin or placebo
From: Effects of ghrelin treatment on exertional dyspnea in COPD: an exploratory analysis
Ghrelin, n = 9 | Placebo, n = 7 | Treatment effect (95 % CI; p valuea) | |
|---|---|---|---|
\({\dot{V}}_{{\rm O}_{2}}\), mL/kg/min | 1.4 (0.9) | 0.1 (1.4) | 1.2 (0.0 to 2.5; 0.048) |
\({\dot{V}}_{{\rm O}_{2}}\), mL/min | 69.3 (48.6) | 8.4 (69.5) | 60.9 (−2.3 to 124.1; 0.058) |
Endurance time, s | 56 (98) | 83 (53) | −27 (−115 to 61; 0.523) |
Dyspnea, Borg | −0.4 (1.3) | −1.0 (1.8) | 0.6 (−1.1 to 2.2; 0.492) |
Plasma LT, mg/dL | 2.8 (7.9) | 2.4 (12.0) | 0.4 (−10.2 to 11.0; 0.937) |
Plasma NA, ng/mL | −0.19 (1.32) | 0.03 (0.94) | −0.22 (−1.49 to 1.05; 0.714) |